Stipple Bio
Cambridge, US · Founded 2021 · Delaware corporation · 17 employees on LinkedIn · 8 known investors
Find your way into Stipple Bio
200 people in our graph share verified history with the Stipple Bio team — schools, employers, funds. One of them is your warm intro.
Paul Jennyunlockedknows Aashish Manglik · together at University of California, San Francisco (overlapped)
×3knows the team · via University of California, San Francisco
×8knows the team · via Stanford University School of Medicine
Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients. The company was founded by cancer biology researchers and focuses on discovering and developing precision cancer medicines.
Founders & leadership
Stipple Bio was founded in 2021 by Aaron Ring and Aashish Manglik.
AR
Aaron RinginCo-Founder
AM
Aashish ManglikinCo-founderAashish Manglik is a physician-scientist with expertise in G protein-coupled receptor biology and biochemistry. He is co-founder of Stipple Bio, which develops targeted oncology therapies for cancer patients.
JL
Jeff LandauinChief Executive Officer
RG
Roland GendroninChief Business Officer
MZ
Michelle ZhanginChief Scientific Officer
Board
VA
AY
Antoine YverBoard director
OH
Owen HughesBoard director
GV
Greg VerdineBoard director
Investors · 8
RA Capital✓ verifiedBostonvia Derek DiRocco · board
Andreessen HorowitzMenlo Park · $500K – $50Mvia Vineeta Agarwala · board
Magnetic VenturesBoston · $1M – $6M
OMX VenturesLincolnshire
Axial VCreportedSan Francisco · $100K – $5M
GV (Google Ventures)reported · 2 sourcesMountain View · $250K – $50M
LoLa Capital PartnersreportedBoston
Nextech Investreported · 2 sourcesZurich · $648K – $3.2M
Reported raises · per SEC filings
Form D private placements$86.6M disclosed across 3 rounds · 2022–2026
▶$65.1MraisedApr 2026 · 15 investors · BiotechnologyRule 506(b)
▶$65.1MraisedApr 2026 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vineeta AgarwalaDirector
- Greg VerdineDirector
- Thilo SchroederDirector
- Owen HughesDirector
- Aaron RingDirector
- Derek DiRoccoDirector
- Jeffrey LandauExecutive Officer, Director
- Offering amount
- $100.2M
- Amount sold
- $65.1M
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$9.5MraisedDec 2024 · 1 investors · BiotechnologyRule 506(b)
▶$9.5MraisedDec 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vineeta AgarwalaDirector
- Antoine YverDirector
- Owen HughesDirector
- Aaron RingExecutive Officer, Director
- Greg VerdineDirector
- Offering amount
- $15M
- Amount sold
- $9.5M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$12MraisedJun 2022 · 7 investors · BiotechnologyRule 506(b)
▶$12MraisedJun 2022 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aaron RingExecutive Officer, Director
- Vineeta AgarwalaDirector
- Offering amount
- $12M
- Amount sold
- $12M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapKrystalbio10 shared keywordsKrystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions. The company operates across the US, Europe, and Japan.
Treeline Biosciences8 shared keywordsTreeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research. The company serves cancer patients through drug discovery and development.
Talus Bio7 shared keywordsTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Fortis Life Sciences6 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Companies competing with Stipple Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Stipple Bio do?
- Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients. The company was founded by cancer biology researchers and focuses on discovering and developing precision cancer medicines.
- Who founded Stipple Bio?
- Stipple Bio was founded by Aaron Ring, Aashish Manglik in 2021.
- Who are Stipple Bio's investors?
- Stipple Bio's investors include RA Capital, Andreessen Horowitz, Magnetic Ventures, OMX Ventures, Axial VC, GV (Google Ventures), LoLa Capital Partners, Nextech Invest.
- How much funding has Stipple Bio raised?
- Stipple Bio has disclosed $86.6M raised across 3 rounds.
- Where is Stipple Bio headquartered?
- Stipple Bio is headquartered in Cambridge, US.